GH Research slides on planned stock sale to fund depression treatments

GH Research

04/02/2025 16:18

**  Shares of GH Research  GHRS.O  down 20.5% to $14.30 on
Tues as co seeks equity to fund development of its treatments
for depression
  
    ** 
  
    ** After the bell Mon, 
    Ireland-based biotech  $150 mln stock offering
  
    ** It plans to use net offering proceeds to invest in
research, clinical and technical development of current and/or
additional product candidates, according to the 
  
    ** Cantor, Stifel and RBC acting as jt bookrunners for the
offering
  
    ** With ~52 mln shares outstanding, co has current market
cap of roughly $760 mln
  
    ** Stock ended 2024 at $7
  
    ** All 5 analysts covering GHRS are bullish with median PT
of $37, LSEG data shows
  
     

(Lance Tupper is a Reuters market analyst. The views expressed
are his own)
((lance.tupper@tr.com 1-646-279-6380))